What is William Blair’s Estimate for LRMR FY2024 Earnings?

Larimar Therapeutics, Inc. (NASDAQ:LRMR) – Equities research analysts at William Blair lifted their FY2024 EPS estimates for Larimar Therapeutics in a research note issued to investors on Wednesday, October 30th. William Blair analyst M. Minter now forecasts that the company will post earnings of ($1.15) per share for the year, up from their prior estimate of ($1.48). The consensus estimate for Larimar Therapeutics’ current full-year earnings is ($1.38) per share. William Blair also issued estimates for Larimar Therapeutics’ Q4 2024 earnings at ($0.29) EPS, Q1 2025 earnings at ($0.32) EPS, Q2 2025 earnings at ($0.35) EPS, Q3 2025 earnings at ($0.38) EPS, Q4 2025 earnings at ($0.42) EPS, FY2025 earnings at ($1.48) EPS, FY2026 earnings at ($1.73) EPS, FY2027 earnings at ($1.74) EPS and FY2028 earnings at ($0.11) EPS.

Larimar Therapeutics (NASDAQ:LRMR) last issued its earnings results on Wednesday, October 30th. The company reported ($0.24) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.13. During the same period last year, the firm earned ($0.21) EPS.

LRMR has been the topic of several other research reports. Baird R W raised shares of Larimar Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 4th. Wedbush began coverage on shares of Larimar Therapeutics in a report on Thursday, October 3rd. They issued an “outperform” rating and a $22.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Larimar Therapeutics in a report on Thursday, October 31st. Oppenheimer assumed coverage on shares of Larimar Therapeutics in a research report on Wednesday, October 16th. They set an “outperform” rating and a $26.00 price target on the stock. Finally, Robert W. Baird began coverage on Larimar Therapeutics in a research report on Wednesday, September 4th. They issued an “outperform” rating and a $16.00 price objective for the company. Nine investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Larimar Therapeutics presently has a consensus rating of “Buy” and an average price target of $20.43.

Larimar Therapeutics Stock Performance

NASDAQ LRMR opened at $7.57 on Monday. The stock’s fifty day moving average is $7.33 and its two-hundred day moving average is $7.82. The firm has a market capitalization of $483.02 million, a P/E ratio of -6.58 and a beta of 0.95. Larimar Therapeutics has a fifty-two week low of $2.18 and a fifty-two week high of $13.68.

Institutional Trading of Larimar Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Quarry LP boosted its position in Larimar Therapeutics by 966.7% in the 2nd quarter. Quarry LP now owns 8,000 shares of the company’s stock valued at $58,000 after buying an additional 7,250 shares during the period. Thoroughbred Financial Services LLC purchased a new stake in shares of Larimar Therapeutics during the second quarter worth approximately $94,000. EntryPoint Capital LLC acquired a new stake in Larimar Therapeutics in the first quarter valued at approximately $106,000. SG Americas Securities LLC purchased a new position in Larimar Therapeutics in the third quarter worth approximately $94,000. Finally, AQR Capital Management LLC acquired a new position in Larimar Therapeutics during the 2nd quarter worth approximately $113,000. Institutional investors and hedge funds own 91.92% of the company’s stock.

Larimar Therapeutics Company Profile

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.